Tarsus prices upsized $75.6M public offering of 5.6M shares at $13.50/share

Tarsus Pharmaceuticals, Inc.

Priced 5,600,000 shares of common stock at $13.50 per share for gross proceeds of $75.6M.
Underwriters granted 30-day option to purchase up to 840,000 additional shares.
Net proceeds expected to be ~$70.6M after underwriting discounts and expenses.
Offering led by BofA Securities, Jefferies, Barclays, and Raymond James as joint book-runners.
Closing expected on May 5, 2022, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.